Aging-focused startup BioAge Labs, Inc. is gaining a key partner in metabolic disease for the upcoming Phase II trial of azelaprag for improving body composition in patients on GLP-1/incretin therapy for obesity. The company announced on 13 February the closing of a large series D venture capital funding round, which it will direct toward development of azelaprag in combination with Eli Lilly and Company’s Zepbound (tirzepatide) and other incretins, and a partnership with Lilly’s Chorus organization.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?